Relationship between Nadir Hematocrit during Cardiopulmonary Bypass and Postoperative Hyperglycemia in Nondiabetic Patients
Background: Hyperglycemia is common after cardiac surgery in both diabetic and nondiabetic patients and is associated with increased morbidity and mortality. Association between nadir hematocrit levels on cardiopulmonary bypass (CPB) and postoperative hyperglycemia is not clear. This study was carried out to determine the relationship between nadir hematocrit during CPB and postoperative hyperglycemia in nondiabetic patients.
Methods: Records of 200 nondiabetic patients undergoing coronary artery bypass grafting operation were retrospectively reviewed. In the first analysis, patients were divided into two subgroups according to the presence or absence of hyperglycemia. Further analysis was made after dividing the patients into 3 subgroups according to nadir hematocrit levels on CPB (less than 20%; 20% to 25%; greater than or equal to 25%).
Results: Compared to patients without hyperglycemia, patients with postoperative hyperglycemia had significantly lower preoperative hematocrit levels (p = 0.004) and were associated with lower nadir hematocrit levels during CPB (p= 0.002). Peak intensive care unit blood glucose levels and number of blood transfusions were significantly higher in patients with nadir hematocrit levels less than 20. (p<0.001 and p<0.001 respectively). Logistic regression analysis demonstrated that nadir hematocrit levels less than 20% (OR 2.9, p=0.009) and allogenic blood transfusion (OR 1.5, p=0.003) were independently associated with postoperative hyperglycemia.
Conclusions: Nadir hematocrit levels on CPB less than 20% and allogenic blood transfusions were independently associated with postoperative hyperglycemia in nondiabetic patients. Patients with a nadir hematocrit levels less than 20 % during CPB should be closely monitored for hyperglycemia in the perioperative period.
Anderson RE, Brismar K, Barr G, Ivert T. 2005. Effects of cardiopulmonary bypass on glucose homeostasis after coronary artery bypass surgery. Eur J Cardiothorac Surg 28:425-30. Baum D, Porte D Jr. 1980. Stress hyperglycemia and the adrenergic regulation of pancreatic hormones in hypoxia. Metabolism 29(Suppl):1176-85.nBoden G. 1997. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10.nBrix-Christensen V. 2001. The systemic inflammatory response after cardiacsurgery with cardiopulmonary bypass in children. Acta Anaesthesiol Scand 45:671-9.nCollier B, Dossett LA, May AK, Diaz JJ. 2008. Glucose control and the inflammatory response. Nutr Clin Pract 23:3-15.nDeFoe GR, Ross CS, Olmstead EM, 2001. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Ann Thorac Surg 71:769-76. Doenst, T., Wijeysundera, D., Karkouti, K., et al. 2005. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thoracic & Cardiovascular Surgery 130:1144-50.nEngoren MC, Habib RH, Zacharias A, et al. 2002. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 74:1180-6.nEstrada CA, Young JA, Nifong LW, Chitwood WR Jr. 2003. Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg. 75:1392-9.nFahy BG, Sheehy AM, Coursin DB. 2009. Glucose control in the intensive care unit. Crit Care Med 37:1769-76.nFransen E, Maessen J, Dentener M, Senden N, Buurman W. 1999. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 116:1233-9.nFurnary AP, Gao G, Grunkemeier GL, et al. 2003. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125:1007-21.nGarg R, Grover A, McGurk S, Rawn JD. 2013. Predictors of hyperglycemia after cardiac surgery in nondiabetic patients. J Thorac Cardiovasc Surg 145:1083-7.nGrossman MI, Moeller HC, Palm L. 1955. Effect of lipemia and heparin on free fatty acid levels of serum in humans. Proc Soc Exp Biol Med 90:106-9.nHabib RH, Zacharias A, Schwann TA, et al. 2005. Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome. Crit Care Med 33:1749-56.nHo J, Sibbald WJ, Chin-Yee IH. 2003. Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med 31(Suppl):S687-97.nKarkouti K, Beattie WS, Wijeysundera DN, et al. 2005. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg 129:391-400.nKarkouti K, Djaiani G, Borger MA, et al. 2005. Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. Ann Thorac Surg 80:1381-7.nKnapik P, Nadziakiewicz P, Urbanska E, Saucha W, Herdynska M, Zembala M. 2009. Cardiopulmonary bypass increases postoperative glycemia and insulin consumption after coronary surgery. Ann Thorac Surg 87:1859-65.nKoch CG, Li L, Duncan AI, et al. 2006. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg 81:1650-7.nKuduvalli M, Oo AY, Newall N, et al. 2005. Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg 27:592-8.nKuntschen FR, Galletti PM, Hahn C, Arnulf JJ, Isetta C, Dor V. 1985. Alterations of insulin and glucose metabolism during cardiopulmonary bypass under normothermia. J Thorac Cardiovasc Surg 89:97-106.nLangouche L, Vanhorebeek I, Van den Berghe G. 2007. Therapy insight: the effect of tight glycemic control in acute illness. Nat Clin Pract Endocrinol Metab 3:270-8.nMcAlister FA, Man J, Bistritz L, Amad H, Tandon P. 2003. Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care 26:1518-24.nMcLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. 2003. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139:802-9.nOuattara A, Lecomte P, Le Manach Y, et al. 2005. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology 103:687-94.nRanucci M, Biagioli B, Scolletta S, et al. 2006. Lowest hematocrit on cardiopulmonary bypass impairs the outcome in coronary surgery: An Italian Multicenter Study from the National Cardioanesthesia Database. Tex Heart Inst J 33:300-5.nRassias AJ, Yeager MP. 2002. Response to "On the Failure of Insulin to Affect Hyperglycemia During Cardiac Surgery." Anest Analg 94:1823-4.nSakharova OV, Inzucchi SE. 2007. Endocrine assessments during critical illness. Crit Care Clin 23:467-90.nSchwartz JD, Shamamian P, Schwartz DS, et al. 1998. Cardiopulmonary bypass primes polymorphonuclear leukocytes. J Surg Res 75:177-82.nSicardi Salomón Z, Rodhe P, Hahn RG. 2006. Progressive decrease in glucose clearance during surgery. Acta Anaesthesiol Scand 50:848-54.nSpeiss BD. 2002. Transfusion and Outcome in Heart Surgery. Ann Thorac Surg 74:986-7.nSwaminathan M, Philips-Bute BG, Conlon PJ, Smith PK, Newman MF, Stafford-Smith M. 2003. The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery. Ann Thorac Surg 76:784-92.nThorell A, Nygren J, Ljungqvist O. 1999. Insulin resistance: a marker of surgical stress. Curr Opin Clin Nutr Metab Care 2:69-78.nTsai AG, Cabrales P, Intaglietta M. 2004. Microvascular perfusion upon Exchange transfusion with stored red blood cells in normovolemic anemic conditions. Transfusion 44:1626-34.nvan Bommel J, de Korte D, Lind A, et al. 2001. The effect of the transfusion of stored RBCs on intestinal microvascular oxygenation in the rat. Transfusion 41:1515-23.nvan den Berghe G, Wouters PJ, Bouillon R, et al. 2003. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31:359-66.nvan den Berghe G, Wilmer A, Hermans G, et al. 2006. Intensive insulin therapy in the medical ICU. N Engl J Med 354:449.nVincent JL, Sakr Y, De Backer D, Van der Linden P. 2007. Efficacy of allogeneic red blood cell transfusions. Best Pract Res Clin Anaesthesiol 21:209-19.nWan S, Yim AP. 1999. Cytokines in myocardial injury: Impact on cardiac surgical approach. Eur J Cardio Thorac Surg 16:107-13.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).